Contact
Please use this form to send email to PR contact of this press release:
ORYZON Announces First Patient Dosed in Phase 1 Trial of the LSD1 inhibitor RG6016 in Small Cell Lung Cancer (SCLC)
TO:
Please use this form to send email to PR contact of this press release:
ORYZON Announces First Patient Dosed in Phase 1 Trial of the LSD1 inhibitor RG6016 in Small Cell Lung Cancer (SCLC)
TO: